Certolizumab pegol

Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α) . Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research[1][2].

Product Specifications

CAS Number

[428863-50-7]

Product Name Alternative

Certolizumab; CDP870

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/certolizumab-pegol.html

Purity

99.30

Solubility

H2O

Smiles

[Certolizumabpegol]

Molecular Weight

(91 kDa)

References & Citations

[1]Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013 Jan;73 (1) :75-97.|[2]Nesbitt A, et al. Mechanism of action of certolizumab pegol (CDP870) : in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 Nov;13 (11) :1323-32.|[3]Kosekli MA, et al. Effects of Certolizumab on Cerulein-Induced Acute Pancreatitis in Rats. Pancreas. 2016 Sep;45 (8) :1120-5.